HCW Biologics Q4 revenue drops sharply on license suspension

Hcw Biologics

31/03/2026 22:14

Overview

U.S. biopharmaceutical firm's Q4 2025 revenue declined sharply yr/yr amid license suspension

Basic EPS for Q4 was -1.02, reflecting continued net losses

Company received $3.5 mln upfront license fee for HCW11-006 and launched two commercial-ready reagents

Outlook

Company says substantial doubt exists about ability to continue as going concern without additional funding

Company expects preliminary human data from HCW9302 Phase 1 trial in first half of 2026

Company plans to appeal Nasdaq notice on minimum bid price non-compliance

Result Drivers

LICENSE SUSPENSION - Revenue decline attributed to one-year suspension of Wugen license agreement, allowing co to market HCW9206 and HCW9201 as reagents

R&D SPENDING - Q4 R&D expenses increased 27% yr/yr, driven by ongoing clinical development activities

REAGENT LAUNCH - Co launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics production

Company press release: ID:nGNX1bkw6c

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Basic EPS
-$1.02


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for HCW Biologics Inc is $2.00, about 454.2% above its March 30 closing price of $0.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)